Clinical trial
Pre-operative Assessment of the Anti-Proliferative Effects and Genomic Alterations of 2 Weeks of Abiraterone Acetate Compared to 2 Weeks of an Aromatase Inhibitor in Post-menopausal Hormone Receptor Positive Operable Breast Cancer
NCT01814865 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pre-operative Assessment of the Anti-Proliferative Effects and Genomic Alterations of 2 Weeks of Abiraterone Acetate Compared to 2 Weeks of an Aromatase Inhibitor in Post-menopausal Hormone Receptor Positive Operable Breast Cancer
- Lead sponsor
- British Columbia Cancer Agency
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- May 31, 2013
- Completion date
- December 31, 2013
- Enrollment
- 0 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
post-menopausal er+ stage i-iiia primary operable breast cancer